Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial
Official title:
Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma
Verified date | May 2023 |
Source | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.
Status | Completed |
Enrollment | 26 |
Est. completion date | October 2018 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | DISEASE CHARACTERISTICS: - Diagnosis of multiple myeloma - Newly diagnosed disease - Durie-Salmon stage II or III disease - Measurable disease, defined by any of the following: - Measurable serum and/or urine M-protein levels documented and available prior to induction therapy - Positive serum free light chain assay - Must have completed a minimum of 3 courses of myeloma specific therapy - Candidate for autologous stem cell transplantation - Patients who have achieved a complete remission at the time of bone marrow harvest for marrow infiltrating lymphocytes (MILs) expansion are not eligible - No evidence of spinal cord compression - Diagnosis of the following cancers are not allowed: - POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) - Non-secretory myeloma (no measurable protein on serum free light chain assay) - Plasma cell leukemia - No amyloidosis PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy = 6 months - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and up to day 180 - Corrected serum calcium < 11 mg/dL and no evidence of symptomatic hypercalcemia - Total bilirubin = 2.0 times upper limit of normal (ULN) - ALT = 2.0 times ULN - Serum creatinine < 2.0 mg/dL - No history of other malignancy within the past 5 years, except adequately treated basal cell or squamous cell skin cancer - No history of autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus) requiring systemic treatment - Hypothyroidism without evidence of Graves' disease or Hashimoto thyroiditis is allowed - No infection requiring treatment with antibiotics, antifungal, or antiviral agents within the past 7 days - No HIV infection - No major organ system dysfunction including, but not limited to, the following: - New York Heart Association class III or IV congestive heart failure - Pulmonary disease requiring the use of inhaled steroids or bronchodilators - Renal, hepatic, gastrointestinal, neurologic, or psychiatric dysfunction that would impair ability to participate in the study PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior hematopoietic stem cell transplantation - At least 3 weeks since prior corticosteroids (i.e., glucocorticoids) - At least 3 weeks since prior myeloma-specific therapy - At least 4 weeks since participation in any clinical trial that involved an investigational drug or device - No concurrent therapy with any of the following: - Corticosteroids (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone [Decadron]) - Inhaled steroids used for treatment of allergic rhinitis or pulmonary disease allowed - Thalidomide - Interferon - Growth factors, interleukins, or other cytokines (except filgrastim [G-CSF] as outlined in the protocol, or erythropoietin) - Cytotoxic chemotherapy agents (except cyclophosphamide for stem cell mobilization and high-dose melphalan) - Immunosuppressive drugs - Experimental therapies - Radiotherapy |
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | National Cancer Institute (NCI) |
United States,
Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hematopoietic Engraftment | Days to absolute neutrophil count > 500 cells per microliter. | Up to 1 year | |
Primary | Disease Response | Percentage of participants with partial or complete response by Bladé criteria. Partial response is defined as a >= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with < 5% plasma cells. | Up to 2 years | |
Primary | Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation | Success rate of expanding MILs in vitro and obtaining a protocol-specified product. | Up to 1 year | |
Secondary | T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC) | ALC counts trending over time. | Days 14, 28, 60, 180, and 360 | |
Secondary | Survival | Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a >= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with < 5% plasma cells. | Up to 129 months | |
Secondary | Pneumococcal-specific Vaccine Responses | CRM-197 Prevnar-specific vaccine responses that measure the T-cell response of the vaccine quantified as %CD3+/CFSE-low/IFN-gamma+. | At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant | |
Secondary | Anti-tumor Immune Responses | Myeloma lysate response that measures the T-cell response quantified as %CD3+/CFSE-low/IFN-gamma+. | At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00568880 -
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00951626 -
A Standardized Nursing Intervention Protocol for HCT Patients
|
N/A | |
Completed |
NCT00898066 -
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
|
N/A | |
Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
Completed |
NCT00313625 -
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00478075 -
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT00301951 -
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
|
Phase 1 | |
Completed |
NCT00937183 -
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
|
N/A | |
Terminated |
NCT00369291 -
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00049374 -
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00004072 -
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
Completed |
NCT00003399 -
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00003396 -
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00003163 -
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
|
Phase 2 | |
Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT00002599 -
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
|
Phase 3 |